Alvotech Teams Up with Advanz Pharma To Launch Eylea Biosimilar
Alvotech partners with Advanz Pharma to market biosimilars AVT06 and AVT29 for eye treatments.
Breaking News
Jun 20, 2024
Mrudula Kulkarni

Alvotech and Advanz Pharma have entered into an exclusive
partnership deal concerning the distribution and marketing of AVT06, Alvotech's
proposed biosimilar to Eylea in its low dose form (2mg), along with AVT29, a
biosimilar candidate for Eylea in its high dose form (8mg). According to the
press release, Eylea is a commonly employed biological treatment for eye
conditions that may result in vision loss or blindness, such as wet AMD,
macular edema, and diabetic retinopathy.
Under this agreement, Alvotech will handle the development
and supply of AVT06 and AVT29, while Advanz Pharma will manage their
registration and commercialization. Advanz Pharma holds exclusive
commercialization rights across Europe, except in Germany and France where the
rights are partially exclusive. The agreement involves an initial payment to
Alvotech, along with additional payments upon achieving specific development
and commercialization milestones.
Anil Okay, Chief Commercial Officer (CCO) of Alvotech, said
that “We value our growing partnership with Advanz Pharma which started early
last year and has now been expanded to a total of seven biosimilar candidates.
We share a common vision for the growth of the biosimilars market and a strong
commitment to providing broader patient access to more affordable biologics.”